Share This Author
Enzalutamide in metastatic prostate cancer before chemotherapy.
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer.
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
A large meta-analysis combining genome-wide and custom high-density genotyping array data identifies 63 new susceptibility loci for prostate cancer, enhancing fine-mapping efforts and providing insights into the underlying biology of PrCa1.
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
- D. Mcleod, P. Iversen, W. See, T. Morris, J. Armstrong, M. Wirth
- MedicineBJU international
- 1 February 2006
To evaluate, in the ongoing EPC trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer.
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median…
- M. Wirth, W. See, D. Mcleod, P. Iversen, T. Morris, K. Carroll
- MedicineJournal of Urology
- 1 November 2004
It is confirmed that bicalutamide provides benefit in patients with locally advanced disease and early or adjuvant hormonal therapy for patients at low risk of disease progression, such as those with localized disease, is not appropriate.
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.
Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
- Joel Aanerud, P. Borghammer, A. Gjedde
- Medicine, BiologyJournal of Cerebral Blood Flow and Metabolism
- 29 February 2012
A possible mechanism of progression from healthy to unhealthy brain aging is established, as the regions most affected by age are the areas that are most vulnerable to neurodegeneration.